Tags : Capmatinib

Novartis’s Capmatinib (INC280) Receives the US FDA’s Breakthrough Therapy Designation

Shots: The US FDA’s BT designation is based on GEOMETRY mono-1 study involves assessing of Capmatinib and the results were also updated in American Society of Clinical Oncology The BT designation is granted to serious or life-threatening disease therapies demonstrate a substantial improvement over existing therapies on one or more significant preliminary research endpoints Capmatinib […]Read More

Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study

Shots: The P-II GEOMETRY mono-1 study results involves assessing of Capmatinib (400mg, bid) in 97 treatment-naive & prior treated patients with LA/metastatic NSCLC harboring a MET exon-14 skipping mutation The P-II GEOMETRY mono-1 study results:  ORR based on BIRC assessment / RECIST v1.1 (68% & 41%); DOR (11.14 mos. & 9.72 mos.), 54% patients showed […]Read More